GLP-1 Receptor Agonist Peptides: Market Outlook and Synthesis Challenges

Few developments in modern pharmaceuticals have generated as much excitement — and supply chain stress — as the rise of glucagon-like peptide-1 (GLP-1) receptor agonists. Drugs like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) have not merely disrupted the diabetes and obesity treatment landscape; they have fundamentally changed how the pharmaceutical industry thinks about peptide-based medicines.

For the peptide synthesis industry, this revolution has created an unprecedented demand shock. As a company at the forefront of GLP-1 peptide production, Helix Therapeutics offers a candid assessment of the market dynamics and the technical challenges that must be overcome to meet global demand.

The Scale of the Opportunity

The numbers are staggering. Semaglutide alone generated revenues of approximately $21 billion in 2024, making it one of the best-selling pharmaceutical products in history. Market analysts project that the GLP-1 drug market could exceed $130 billion annually by 2030, with dozens of novel peptide and peptidomimetic candidates currently in clinical development.

This demand is not limited to the originator products. A rapidly expanding ecosystem of biosimilar, follow-on, and novel GLP-1 analogue programmes is driving enormous demand for multi-kilogram quantities of GLP-1-related peptides at every stage of development — from early SAR studies requiring milligram quantities to Phase III supply requiring hundreds of kilograms per year.

The Synthesis Challenge

GLP-1 receptor agonist peptides are not trivial to synthesise. Semaglutide, for example, is a 31-amino acid peptide with a C18 fatty diacid chain attached via a linker to Lys26. This lipidation is critical to its pharmacokinetics but adds significant complexity to the synthesis and purification workflow.

Key synthesis challenges for GLP-1-class peptides include:

• Difficult sequences: Several segments within GLP-1 analogues are highly aggregation-prone, leading to incomplete couplings and deletions unless specialised protocols (pseudoproline dipeptides, chaotropic additives, microwave assistance) are employed.
• Lipidation chemistry: Site-specific attachment of fatty acid chains requires orthogonal protecting group strategies that are more complex than standard Fmoc-SPPS and demand specialist expertise.
• Purification at scale: The amphiphilic character of lipidated peptides makes preparative HPLC purification challenging — standard C18 methods often require mobile phase optimisation and temperature control to achieve the required purity specifications.
• Scale-up reproducibility: Ensuring that synthesis and purification methods developed at the milligram scale translate reliably to kilogram GMP production requires extensive process development work.

How Helix Therapeutics Is Responding

Over the past 18 months, Helix has invested significantly in developing robust, scalable protocols for GLP-1-class peptides. Our process chemistry team has validated microwave-assisted SPPS protocols for the aggregation-prone central segment of semaglutide (residues 8–22) that achieve >99% coupling efficiency per step — a critical prerequisite for acceptable crude purity at kilogram scale.

For lipidation, we have developed a two-stage approach: Fmoc-SPPS of the peptide backbone with Dde-protected Lys26, followed by selective deprotection and on-resin fatty acid chain elongation. This eliminates the need for solution-phase lipidation and simplifies downstream purification significantly.

The recent installation of our new large-scale GMP reactor (see our recent announcement) positions Helix to support GLP-1 clinical programmes at all stages from Phase I through commercialisation.

Looking Ahead

The GLP-1 era is just beginning. Beyond obesity and diabetes, GLP-1 receptor agonists are being investigated for cardiovascular disease, non-alcoholic steatohepatitis (NASH), Alzheimer's disease, and addiction — applications that could expand the addressable market further still.

For peptide synthesis companies, the challenge is not just capacity but capability: the technical depth to handle complex lipidated and modified sequences at GMP quality, and the regulatory experience to support global drug development programmes. These barriers to entry mean that established, highly capable partners like Helix Therapeutics are well positioned to benefit from this secular growth trend.

We welcome conversations with pharmaceutical and biotech companies working on GLP-1 programmes or other complex therapeutic peptides. Please reach out to our scientific team at info@helixtherapeutics.com.